# OnCo record nct06530303 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06530303/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06530303", "NCT06530303" ;
  schema:name "Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer"@en ;
  schema:alternateName "BAH248"@en ;
  schema:description "A phase 1/2 trial of cyclophosphamide, fludarabine, aldesleukin (high-dose IL-2) and pembrolizumab in colorectal cancer, run by Essen Biotech, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06530303/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06530303> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest", "colorectal-deep-dive" ;
  onco:phase "1/2" ;
  onco:cancers <https://onco.cc/cancers/rectal-cancer/>, <https://onco.cc/cancers/colon-cancer/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:drugs <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/fludarabine/>, <https://onco.cc/drugs/aldesleukin/>, <https://onco.cc/drugs/pembrolizumab/> .